Table 2.

Average Annual Cases of Neonatal Tetanus and TT2 Coverage in Meningitis Belt Countries That Have Introduced or Have Yet to Introduce PsA-TT

Campaign AreaAverage Annual Cases of NT, No.
TT2 Coverage, %
2009–20112012–2013% Change2009–20112012–2013% Change
No PsA-TT campaignsa121.9139.5+14.4%85.679.2−7.4%
Before campaignAfter campaign% changeBefore campaignAfter campaign% change
Campaigns in part of countryb6468+6.5%86.685.8−0.9%
Campaigns covering all countryc260.2194.5−25.4%82.281.0−2.5%
Campaign AreaAverage Annual Cases of NT, No.
TT2 Coverage, %
2009–20112012–2013% Change2009–20112012–2013% Change
No PsA-TT campaignsa121.9139.5+14.4%85.679.2−7.4%
Before campaignAfter campaign% changeBefore campaignAfter campaign% change
Campaigns in part of countryb6468+6.5%86.685.8−0.9%
Campaigns covering all countryc260.2194.5−25.4%82.281.0−2.5%

Abbreviations: NT, neonatal tetanus; PsA-TT, group A meningococcal conjugate vaccine; TT2, second dose of tetanus toxoid.

a Côte d'Ivoire, Ethiopia, Mauritania, Democratic Republic of Congo, Guinea, Central African Republic.

b Cameroon, Togo, Benin, Ghana.

c Burkina Faso, Mali, Niger, Gambia, Chad, Senegal.

Table 2.

Average Annual Cases of Neonatal Tetanus and TT2 Coverage in Meningitis Belt Countries That Have Introduced or Have Yet to Introduce PsA-TT

Campaign AreaAverage Annual Cases of NT, No.
TT2 Coverage, %
2009–20112012–2013% Change2009–20112012–2013% Change
No PsA-TT campaignsa121.9139.5+14.4%85.679.2−7.4%
Before campaignAfter campaign% changeBefore campaignAfter campaign% change
Campaigns in part of countryb6468+6.5%86.685.8−0.9%
Campaigns covering all countryc260.2194.5−25.4%82.281.0−2.5%
Campaign AreaAverage Annual Cases of NT, No.
TT2 Coverage, %
2009–20112012–2013% Change2009–20112012–2013% Change
No PsA-TT campaignsa121.9139.5+14.4%85.679.2−7.4%
Before campaignAfter campaign% changeBefore campaignAfter campaign% change
Campaigns in part of countryb6468+6.5%86.685.8−0.9%
Campaigns covering all countryc260.2194.5−25.4%82.281.0−2.5%

Abbreviations: NT, neonatal tetanus; PsA-TT, group A meningococcal conjugate vaccine; TT2, second dose of tetanus toxoid.

a Côte d'Ivoire, Ethiopia, Mauritania, Democratic Republic of Congo, Guinea, Central African Republic.

b Cameroon, Togo, Benin, Ghana.

c Burkina Faso, Mali, Niger, Gambia, Chad, Senegal.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close